Drug Trial Radar · NCT04912596
Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma
Last checked: Nov 20, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
148
Planned (sponsor's estimate)
Start
Aug 15, 2022
Primary completion
Jan 31, 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Intech Biopharm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA (albuterol sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation manufactured by two different manufacturers using methacholine bronchoprovocation challenge test in patients with stable mild asthma.
Conditions
- Mild Asthma
Interventions
Albuterol Sulfate inhalation aerosol 108 mcg per actuationDrug
equal to albuterol 90 mcg/puff, MDI
Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuationDrug
equal to albuterol 90 mcg/puff, MDI
Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation PlaceboOther
MDI
Albuterol Sulfate inhalation PlaceboOther
MDI
MethacholineOther
Methacholine 100 mg/vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-dose PC20 ConcentrationTime frame: 15 minutes post-dose
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Dr. Jivraj Mehta Smarak Health Foundation
Ahmedabad, India · Not yet recruiting
KLEs Dr Prabhakar Kore Hospital & MRC
Belagāve, India · Not yet recruiting
NRS Medical College and Hospital
Kolkata, India · Not yet recruiting
Medical College and Hospital
Kolkata, India · Not yet recruiting
Aakash Healthcare Super Specialty Hospital
New Delhi, India · Not yet recruiting
Pimpri Chinchwad Municipal Corporation Post Graduate Institute Yashwantrao Chavan Memorial Hospital
Pune, India · Not yet recruiting
Kothrud Hospital
Pune, India · Not yet recruiting
Ashirwad Hospital and Research Centre
Ulhasnagar, India · Not yet recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Tamshui Mackay Memorial Hospital
New Taipei City, Taiwan · Recruiting
Taipei Medical University Hospital
Taipei, Taiwan · Recruiting
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.